Avoid or Embrace? Practice Effects in Alzheimer’s Disease Prevention Trials

Demonstrating a slowing in the rate of cognitive decline is a common outcome measure in clinical trials in Alzheimer’s disease (AD). Selection of cognitive endpoints typically includes modeling candidate outcome measures in the many, richly phenotyped observational cohort studies available. An impor...

Descripción completa

Detalles Bibliográficos
Autores principales: Aschenbrenner, Andrew J., Hassenstab, Jason, Wang, Guoqiao, Li, Yan, Xiong, Chengjie, McDade, Eric, Clifford, David B., Salloway, Stephen, Farlow, Martin, Yaari, Roy, Cheng, Eden Y. J., Holdridge, Karen C., Mummery, Catherine J., Masters, Colin L., Hsiung, Ging-Yuek, Surti, Ghulam, Day, Gregory S., Weintraub, Sandra, Honig, Lawrence S., Galvin, James E., Ringman, John M., Brooks, William S., Fox, Nick C., Snyder, Peter J., Suzuki, Kazushi, Shimada, Hiroyuki, Gräber, Susanne, Bateman, Randall J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244171/
https://www.ncbi.nlm.nih.gov/pubmed/35783127
http://dx.doi.org/10.3389/fnagi.2022.883131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244171/
https://www.ncbi.nlm.nih.gov/pubmed/35783127
http://dx.doi.org/10.3389/fnagi.2022.883131

Ejemplares similares